EBD GmbH is part of the Knowledge & Networking Division of Informa PLC


This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Informa
 
Biotech Showcase 2015 EBD Group Demy-Colton
Share/Follow Us
Share this:
Follow this event:

Biotech Showcase™ 2016 Program Overview

www.ebdgroup.com/bts/program
Sunday, January 10, 2016
1:00–5:00 pm
Additional Program
Biotech Showcase™ pre-event

This workshop is focused on delivering results and securing funding at All Levels: Boards, Angels, VCs, Corporate Partners and Other Sources of Funds, with four hours of intensive and interactive discussion, on-your-feet sessions, war stories and insights aimed at folks looking for financing. It is designed to accelerate your funding activities and eliminate unnecessary noise.

Preregistration is required, more information can be found here.

3:00–6:00 pm
Level 4, Cyril Magnin Foyer

All Biotech Showcase attendees are invited to pick up name badges prior to the beginning of the conference on Monday.

Monday, January 11, 2016
7:00 am
Level 4, Cyril Magnin Foyer
Registration Opens and Continental Breakfast
8:00–8:55 am
Workshops
The age of virtual pharma: Challenges and solutions for investor directors and successful boards

Public and private funding is supporting a large percentage of the R&D pipeline but there are too many potential products in development for pharma to license them all. The inability of pharma to absorb new assets through licensing and partnerships has not compromised future medicines development but has it inhibited further investment? We think smart small and mid-sized biotech companies have found new ways to work that will keep their boards and investors confident that there will be an exit—even if it is not the exit originally targeted. Biotech companies now need to take products through clinical development to launch. How will this be achieved? How can companies respond to current and future challenges in an increasingly virtual and fragmented world? How can they increase the chances of a successful exit for investors and management?

Four highly successful board members will provide insight, commentary and answers to these questions while exploring possible solutions on how to manage the relationship between investor, management boards and scientific innovation to secure successful outcomes.

Moderator:
Flic Gabbay – Managing Partner and Co-Founder, TranScrip

Panelists:
  • Frank Armstrong – Chairman, Xceleron, Summit Therapeutics, Redx and Faron Pharmaceuticals; Board Member, TranScrip
  • Colin Broom – CEO, Nabriva Therapeutics
  • Michael Butler – CEO, Xceleron
  • Julia Gregory – CEO, ContraFect
Share this:Email this pageShare this on LinkedInShare this on Twitter
Alzheimer's disease: Has the tide turned?

Over the past 10 years, Alzheimer's disease has seen an unprecedented level of failures in late stage clinical trials. This has, in part, been attributed to a focus on a narrow range of therapeutic targets, addressing the wrong stage of the disease, and inadequate selection of trial participants. This in turn has led to a systemic skepticism among the investors and in pharma with regards to Alzheimer's disease. At the same time, public and government awareness about the huge unmet clinical need in Alzheimer's continues to increase. In addition, there is a new optimism in the field due to recent advances in the understanding of the disease and, hence, more targeted approaches to developing products. This session will question whether this interest is translating into increased interest in investment and M&A. Furthermore, the panelists will discuss what investors are looking for and how companies can best position themselves.

Moderator:
Charles Stacey – Co-Chair, AASCC - Alzheimer's Association Small Company Consortium; CEO, Accera

Panelists:
  • Neta Batscha – Analyst, RA Capital Management
  • Andrew Fein – Senior Biotechnology Analyst, HC Wainwright
  • Jim Hendrix – Director, Global Science Initiatives, Alzheimer's Association
  • Guy Seabrook – VP, Neuroscience Innovation, Johnson & Johnson Innovation
Share this:Email this pageShare this on LinkedInShare this on Twitter
8:00 am–6:00 pm
One-to-one Meetings ►

Hilton Union Square
333 O'Farrell Street
Level 2, Ballroom

8:00–9:50 am
Regenerative Medicine and Advanced Therapies State of the Industry Briefing
Introduction and industry update

Speakers:
  • Morrie Ruffin – Managing Director, Alliance for Regenerative Medicine
  • Edward Lanphier – President and CEO, Sangamo BioSciences; Chairman, Alliance for Regenerative Medicine
Share this:Email this pageShare this on LinkedInShare this on Twitter
The 2016 sector forecast: Upcoming clinical data events

This session features CEOs and senior executives from leading companies in the regenerative medicine and advanced therapies sector for a forward-looking discussion of expected clinical data events in 2016 and beyond. Panelists will address key issues related to continuing momentum in the sector as well as unique strategies and partnerships that will be required for success going forward.

Moderators:
Jason Kolbert – Head, Healthcare Research and Senior Managing Director, Maxim Group
Jason McCarthy – Equity Research Analyst, Biotechnology, Maxim Group

Panelists:
  • Silviu Itescu – CEO, Mesoblast
  • Sven Kili – VP and Head, Gene Therapy Development, GlaxoSmithKline
  • Gil Van Bokkelen – Chairman and CEO, Athersys
  • Jeffrey Walsh – COO, bluebird bio
  • Susan Washer – CEO, AGTC
Share this:Email this pageShare this on LinkedInShare this on Twitter
The promise of Regenerative Medicine and Advanced Therapies in oncology

This in-depth session will examine the progress of regenerative medicine and advanced therapies specifically as the field relates to the area of oncology. The panel's expert speakers will discuss a number of key hurdles on the path to commercialization including reimbursement and market access and what progress can be expected in the sector in the coming year.

Moderator:
Joshua Schimmer – Managing Director and Senior Research Analyst, Piper Jaffray

Panelists:
  • Jeffrey Abbey – President and CEO, Argos Therapeutics
  • Usman Azam – Global Head, Cell and Gene Therapies Unit, Novartis
  • André Choulika – Chairman and CEO, Cellectis
  • Gregg Sando – Founder and CEO, Cell Medica
Share this:Email this pageShare this on LinkedInShare this on Twitter
8:00 am–12:00 pm Company Presentations ►

Private Biotech
Public Biotech

12:00–1:30 pm
Lunch Plenary
The great pricing debate: Navigating through an industry sea change

The biopharmaceutical sector is surrounded by a shifting landscape of powerful players. Payers, physicians, and providers are larger and more integrated than ever, while government involvement in healthcare is all-encompassing. Although not yet at "single-payer," we are down to "six-payer" following a new spate of mergers. Localization of healthcare is diminishing, as the idea of the "mom-and-pop" physician becomes obsolete. Patients have watched their defined benefits become defined contributions. Other national healthcare industries seem to have figured out how to shelve their self-interests, and evolve. We continue to stand alone; fragmented and self-interested. Where, as an industry, do we go from here?

Moderator:
Mike Griffith – Executive VP, inVentiv Health; President, inVentiv Health Commercial Divison

Panelists:
  • Gregg H. Alton – Executive VP, Corporate and Medical Affairs, Gilead Sciences, Inc.
  • Ron Cohen – CEO, Acorda Therapeutics; Chairman, Biotechnology Industry Organization (BIO)
  • Keith Kelly – Managing Director and Head, Pricing and Market Access, Campbell Alliance/inVentiv Health Consulting
  • Sara Radcliffe – President and CEO, California Life Sciences Association (CLSA)
  • Beth L. Roberts – Partner, Hogan Lovells
Share this:Email this pageShare this on LinkedInShare this on Twitter
1:45–5:30 pm Company Presentations ►

Private Biotech
Public Biotech

Tuesday, January 12, 2016
7:00 am
Level 4, Cyril Magnin Foyer
Registration Opens and Continental Breakfast
8:00–8:55 am
Workshops
Corporate venture: Pharma's eye on the early stage

In the pharmaceutical industry, corporate VC is enjoying a decade-long boom. Almost every big pharmaceutical company now has a corporate fund and one or more of these funds seem to be part of almost every Series A financing. This workshop will explore the role of corporate venture in the industry today and the way it allows pharma to keep an eye on, and influence, the industry's future technologies and products.

Moderator:
Steve Dickman – CEO, CBT Advisors

Panelists:
  • Simon Meier – Investment Director, F. Hoffmann-La Roche AG
  • Marian Nakada – VP, Venture Investments, Johnson & Johnson Innovation
  • Ed Torres – Managing Partner, Lilly Ventures
  • Sam Wu – Managing Director, MedImmune Ventures
Share this:Email this pageShare this on LinkedInShare this on Twitter
The Life Sciences Report 2016 small-cap watchlist

Join senior healthcare analysts and this panel of experts as they discuss their top small-cap biotech picks for 2016. This panel of biotech analysts will articulate why their favorite small-cap ideas are good investment opportunities. Follow the progress of the "Watchlist" throughout the year on The Life Sciences Report. This is a must-attend for investors looking for new ideas in the life sciences industry.

Moderator:
Reni Benjamin – Senior VP, Senior Biotechnology Analyst, Raymond James Financial, Inc.

Panelists:
  • Mara Goldstein – Managing Director, Senior Healthcare Analyst, Head of Healthcare Equity Research, Cantor Fitzgerald
  • Michael G. King, Jr. – Managing Director and Senior Biotechnology Analyst, JMP Securities
  • Raghuram "Ram" Selvaraju – Analyst, Rodman & Renshaw Research
  • George Zavoico – Senior Analyst, Jones Trading, International Services LLC
Share this:Email this pageShare this on LinkedInShare this on Twitter
London and the UK: A global hub for life sciences and investment

London and the UK have seen a resurgence in life science capital raising in the last two years after a decade of sparse activity. Leading UK companies like Circassia and Immunocore have been able to access deeper pockets of public and private capital, there has been an impressive wave of capital raising from smaller AIM-listed life science companies and even US life science related companies such as Allied Minds, PureTech and Verseon have recently completed large IPOs on the London Stock Exchange.

This workshop will address the questions of the sustainability of this re-emergence, how the structure of the UK market and life science company profiles differ from that of the US and what role London and the UK can play as a global hub for the sector and, in particular, in life science capital raising in the future.

Moderator:
Chris Mayo – CFA, Technology and Life Sciences, Primary Markets, London Stock Exchange Group

Panelists:
  • Steve Bates – CEO, UK Bioindustry Association
  • Eliot Forster – Chair, MedCity; CEO, Immunocore Ltd
  • Saku Saha – Fund Manager, Woodford Investment Management
  • Paul Tomasic – Managing Director, European Head, Healthcare, Global Investment Banking, RBC Capital Markets
  • Daphne Zohar – CEO, PureTech Health PLC
Share this:Email this pageShare this on LinkedInShare this on Twitter
8:00 am–6:00 pm
One-to-one Meetings ►

Hilton Union Square
333 O'Farrell Street
Level 2, Ballroom

8:00–9:15 am
Medtech Showcase State of the Industry Report
Medtech Showcase State of the Industry Report

The rise of personalized, or precision, medicine is creating a convergence of traditional therapeutic biopharmaceutical products with innovative diagnostic and/or drug delivery technologies.

In recognition of this convergence, executives with deep experience in the device and diagnostic industry will discuss the latest technologies with an eye to how they will help advance biopharmaceutical innovation. By addressing regulatory issues related to combination products, the cultural challenges of working across the medical technology and biopharm sectors, financing and intellectual property considerations, this plenary will help provide an understanding of the opportunities, as well as the risks, that these new technologies bring.

Moderator:
Vicki Anastasi – VP and Global Head, Medical Device and Diagnostics Research, ICON

Panelists:
  • Patrick Daly – Board Member, AdvaMed; President and CEO, Cohera Medical
  • Andrew Fish – Executive Director, AdvaMedDx; Senior Executive, AdvaMed
  • Bill Murray – President, MDIC
Share this:Email this pageShare this on LinkedInShare this on Twitter
8:00 am–12:00 pm Company Presentations ►

Private Biotech
Public Biotech

12:00–1:30 pm
Lunch Plenary
State of the industry: It's different this time

Since the emergence of the Biotech Bull Market everyone has been asking: "Is it different this time?" The answer is an emphatic "yes." The emergence of a cadre of profitable biotech companies is changing the traditional dynamic between big pharma, biotech and investors. How will the ecosystem continue to evolve as the biotech industry comes of age, and how will all of the players fund and source innovation in the decade to come?

Moderator:
Ben Bonifant – Founder and Partner, Triangle Insights Group

Panelists:
  • Tim Herpin – Head, Transactions, Business Development Operations, AstraZeneca
  • Philippe Lopes-Fernandes – Senior VP, Head, Global Licensing and Business Development, Merck KGaA, Darmstadt, Germany
  • Diego Miralles – Head, Johnson & Johnson Innovation
  • Dennis Purcell – Founder and Senior Advisor, Aisling Capital
  • Luke Timmerman – Founder and Editor, Timmerman Report
Share this:Email this pageShare this on LinkedInShare this on Twitter
1:45–5:30 pm Company Presentations ►

Private Biotech
Public Biotech

4:30–5:30 pm
Medtech Showcase Workshop
Advanced medical technology: What investors need to know

By reducing adverse side effects, increasing compliance and identifying the right therapy for each patient, advanced drug delivery and diagnostics are key tools in our quest to improve the precision of advanced therapeutics. This session will highlight the investment opportunities in this exciting sector and identify the key factors investors and partners are looking for in companies.

Moderator:
Christian Haller – President, RavenOye Group

Panelists:
  • Stephen Dunn – Senior Managing Director, Research, LifeTech Capital
  • Vijay Pande – General Partner, Andreessen Horowitz
  • Phyllis E. Whiteley – Venture Partner, Mohr Davidow Ventures
  • Peter Young – Executive-in-Residence, Pappas Capital
Share this:Email this pageShare this on LinkedInShare this on Twitter
Wednesday, January 13, 2016
7:00 am
Level 4, Cyril Magnin Foyer
Registration Opens and Continental Breakfast
8:00–8:55 am
Workshops
FDA 2016: New FDA Commissioner, PDUFA reauthorization process and biomarkers

What are the important regulatory issues in 2016 for investors? With the new Commissioner, Dr. Robert Califf, there are many issues that need to be addressed: the 21st Century Cures law that has passed the House but has not been brought to the Senate, user fee reauthorization hearings, and the push to formalize the use of biomarkers in development, just to name a few. Will they, and what will it mean for biopharma companies and their stakeholders?

Moderator:
Joseph V. Gulfo – Executive Director, Rothman Institute of Innovation and Entrepreneurship; Farleigh Dickinson University and Author

Panelists:
  • David M. Fox – Partner, Hogan Lovells
  • Nancy Bradish Myers – President and Founder, Catalyst Healthcare Consulting
  • Sara Radcliffe – President and CEO, California Life Sciences Association (CLSA)
Share this:Email this pageShare this on LinkedInShare this on Twitter
Investing in the immuno-oncology revolution: Follow the T cells

Checkpoint inhibitors and CAR-Ts have transformed oncology today, and, in fact, immune-oncology is becoming front-line for many cancers. However, checkpoint inhibitors are only realizing 20–40% response rates. In order to realize higher response rates, getting T cells to the tumor by trafficking them there, getting the tumor to generate them, or both, is a must. New research is looking at combining cancer vaccines with checkpoint inhibitors to activate and generate higher levels of T cells to increase efficacy. And in fact, recent deals to combine vaccines and inhibitors suggest the potential of such combinations.

Moderator:
Andrew Baum – Global Head, Healthcare Research, Citi

Panelists:
  • Jeffrey M. Bockman – VP, Defined Health
  • J. Joseph Kim – President, CEO, Director, Inovio Pharmaceuticals
  • Marc Mansour – CEO, ImmunoVaccine Inc.
Share this:Email this pageShare this on LinkedInShare this on Twitter
8:00 am–5:00 pm
One-to-one Meetings ►

Hilton Union Square
333 O'Farrell Street
Level 2, Ballroom

8:00–9:00 am
Digital Health Showcase State of the Industry Report
At the intersection of technology and medicine

The convergence between technology and medicine is poised to have a profound effect on healthcare which would impact all of the stakeholders in the healthcare system including physicians, payers, pharma companies, and patients. Even those involved in the development of small molecules may find themselves needing to be familiar with digital health which may increasingly be used in clinical trials.

Because digital therapeutics will play a key role in the evolution of how disease will be monitored and treated in the future, this session will highlight how this emerging sector will interact with conventional biopharma companies.

Moderator:
Yarmela Pavlovic – Partner, Hogan Lovells

Panelists:
  • Vivek Bhatt – Chief Technology Officer, GE Healthcare Life Care
  • Eric Elenko – Executive VP, Science and Technology, PureTech
  • Christine Lemke – Chief Product Officer, Evidation Health
  • Kevin McRaith – CEO, WellDoc
Share this:Email this pageShare this on LinkedInShare this on Twitter
8:00 am–12:00 pm Company Presentations ►

Private Biotech
Public Biotech

10:00–11:00 am
Digital Health Showcase Workshop
Who's investing in digital medicine?

Moderator:
Steve Dickman – CEO, CBT Advisors

Panelists:
  • Zack Lynch – General Partner, JAZZ Venture Partners
  • Aaron Nelson – General Partner, dRx Capital
  • Ajit Singh – Partner, Artiman Ventures
Share this:Email this pageShare this on LinkedInShare this on Twitter
11:00–11:45 am
Fireside chat

Interviewed by:
Steve Dickman – CEO, CBT Advisors

Interviewee:
Vijay Pande – General Partner, Andreessen Horowitz

Share this:Email this pageShare this on LinkedInShare this on Twitter
11:45 am–12:15 pm
Digital Health Showcase Discussion
Top 10 digital health trends: Implications for early to mid-stage biopharma

Speakers:
  • Jay Goldman – Managing Director, Sensei Labs, Klick Health
  • Michael Young – VP, Strategy, Sensei Labs, Klick Health
Share this:Email this pageShare this on LinkedInShare this on Twitter
12:00–1:30 pm
Lunch Plenary
Bubble trouble? Have the biotech bulls had their run?

After posting its worst performance in 13 years in the third quarter, many are saying the biotech bull market has run its course. But the appetite for new issues hasn't abated; biotech IPOs outperformed the sector as a whole in Q3 and the IPO queue remains crowded. And so far, the public market volatility hasn't significantly impacted private investment in terms of number of deals or valuations. So what should investors expect for 2016? Will the bull market recover or will the bears take control?

Moderator:
Eric W. Blanchard – Partner, Covington & Burling LLP

Panelists:
  • Asthika Goonewardene – Senior Biotechnology Analyst, Bloomberg Intelligence
  • Art Pappas – Managing Partner, Pappas Ventures
  • Evonne Sepsis – Managing Director, ESC Advisors
  • Alex Zisson – Partner, Thomas McNerney & Partners
Share this:Email this pageShare this on LinkedInShare this on Twitter
1:00–1:45 pm
Digital Health Showcase Workshop
The regulatory pathway: Is it getting clearer?

Moderator:
Yarmela Pavlovic – Partner, Hogan Lovells

Panelists:
  • Jon Brilliant – CFO, Bigfoot Biomedical
  • Romain Marmot – Chief Operations Officer, Voluntis, Inc.
  • Valeska Schroeder – Senior VP, Product Management, Vital Connect
Share this:Email this pageShare this on LinkedInShare this on Twitter
4:00–5:00 pm
Digital Health Showcase Workshop
A look at big pharma's interest in digital medicine

How is big pharma looking at the emerging digital medicine technologies? While many clinical trials are already using the technology, when and to what extent is pharma planning to incorporate digital medicine tools in drug delivery, patient monitoring and other therapeutic applications?

Moderator:
Melissa Bianchi – Partner, Hogan Lovells

Panelists:
  • Daniel Gandor – Head, Takeda Digital Accelerator, Takeda Pharmaceuticals International
  • Matthew Owens – Global Head Legal, Strategic Partnerships and Digital Medicine, Novartis
Share this:Email this pageShare this on LinkedInShare this on Twitter
1:45–5:00 pm Company Presentations ►

Private Biotech
Public Biotech

5:00–6:00 pm
Level 4, Cyril Magnin Foyer
Closing Reception
Arrow Up

Follow this event:
Sign up now
For news and updates

Privacy Policy and Cookies Terms of Use

Home | Contact Us | Site Map
See more upcoming conferences ►

EBD Group's Family of Events

© 2009–2016 EBD Group, Inc.
Privacy Policy and Cookies
Terms of Use